Parabilis Medicines, Inc. (PBLS)

Parabilis Medicines, Inc. is trading at $38.93, up 4.59% on the session. The 50 day average sits at $n/a and the 200 day at $n/a, which puts the stock in a mixed technical position. RSI is at 62.5, which reads as strong, and MACD is bullish crossover. Volume is below average.

The nearest support is around $26.42 with resistance near $37.99, so that band frames the current range. Average daily movement is roughly $2.49, or about 6.4% of the share price, which is what any stop placement has to allow for. The overall health score of 56 out of 100 combines a trend score of 50, momentum of 88 and a risk score of 22.

Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable. Its pipeline includes functional inhibitors of intracellular protein-protein interactions, targeted protein degraders, and targeted radiopharmaceuticals, with a lead clinical program, FOG-001, that acts as a TCF-blocking beta-catenin inhibitor for cancer treatment. The company integrates artificial intelligence and data science into drug discovery, trial design, and clinical strategy optimization. Parabilis Medicines serves clients in the healthcare and life sciences industries, including clinical research organizations and medical professionals involved in oncology and cancer treatment. The company was founded in 2015 and is based in Cambridge, Massachusetts.